Ignite Creation Date:
2024-05-05 @ 4:47 PM
Last Modification Date:
2024-10-26 @ 9:24 AM
Study NCT ID:
NCT00310531
Status:
COMPLETED
Last Update Posted:
2014-12-30
First Post:
2006-03-31
Brief Title:
3-year Study of Menostar Versus Evista to Prevent Osteoporosis in Post-menopausal Women
Sponsor:
Bayer
Organization:
Bayer
Study Overview
Official Title:
A Multicenter Double-Blind Double-Dummy Randomized Active- Controlled 3-Year Study to Evaluate the Antiresorptive Efficacy Safety and Tolerability of a Ultra-Low Dose Estradiol Transdermal Delivery System Releasing 0014 mg Day Versus Oral Raloxifene Hydrochloride 60 mg Day - as a Therapy for the Prevention of Osteoporosis in Postmenopausal Female Osteopenic Patients
Status:
COMPLETED
Status Verified Date:
2014-12
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The aim of this trial is to investigate whether the Menostar patch is as safe and effective in the prevention of bone loss in postmenopausal women as raloxifen a drug already registered for prevention and treatment of osteoporosis
Detailed Description:
The study has previously been posted by Schering AG Germany Schering AG Germany has been renamed to Bayer Schering Pharma AG GermanyBayer Schering Pharma AG Germany is the sponsor of the trial
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| 306871 | None | None | None |